Cargando…
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152953/ https://www.ncbi.nlm.nih.gov/pubmed/34788987 http://dx.doi.org/10.3324/haematol.2021.280026 |
| _version_ | 1784717748884996096 |
|---|---|
| author | Kohn, Milena Delord, Marc Chbat, Maureen Guemriche, Amina Merabet, Fatiha Roupie, Anne-Laure Lombion, Naelle Farhat, Hassan Longval, Thomas Cabannes-Hamy, Aurélie Lambert, Juliette Marque-Juillet, Stéphanie Raggueneau, Victoria Osman, Jennifer Spentchian, Marc Rigaudeau, Sophie Rousselot, Philippe Besson, Caroline |
| author_facet | Kohn, Milena Delord, Marc Chbat, Maureen Guemriche, Amina Merabet, Fatiha Roupie, Anne-Laure Lombion, Naelle Farhat, Hassan Longval, Thomas Cabannes-Hamy, Aurélie Lambert, Juliette Marque-Juillet, Stéphanie Raggueneau, Victoria Osman, Jennifer Spentchian, Marc Rigaudeau, Sophie Rousselot, Philippe Besson, Caroline |
| author_sort | Kohn, Milena |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9152953 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91529532022-06-13 A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia Kohn, Milena Delord, Marc Chbat, Maureen Guemriche, Amina Merabet, Fatiha Roupie, Anne-Laure Lombion, Naelle Farhat, Hassan Longval, Thomas Cabannes-Hamy, Aurélie Lambert, Juliette Marque-Juillet, Stéphanie Raggueneau, Victoria Osman, Jennifer Spentchian, Marc Rigaudeau, Sophie Rousselot, Philippe Besson, Caroline Haematologica Letter to the Editor Fondazione Ferrata Storti 2021-11-18 /pmc/articles/PMC9152953/ /pubmed/34788987 http://dx.doi.org/10.3324/haematol.2021.280026 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Kohn, Milena Delord, Marc Chbat, Maureen Guemriche, Amina Merabet, Fatiha Roupie, Anne-Laure Lombion, Naelle Farhat, Hassan Longval, Thomas Cabannes-Hamy, Aurélie Lambert, Juliette Marque-Juillet, Stéphanie Raggueneau, Victoria Osman, Jennifer Spentchian, Marc Rigaudeau, Sophie Rousselot, Philippe Besson, Caroline A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia |
| title | A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia |
| title_full | A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia |
| title_fullStr | A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia |
| title_full_unstemmed | A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia |
| title_short | A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia |
| title_sort | third anti-sars-cov-2 mrna dose does not overcome the pejorative impact of anti-cd20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152953/ https://www.ncbi.nlm.nih.gov/pubmed/34788987 http://dx.doi.org/10.3324/haematol.2021.280026 |
| work_keys_str_mv | AT kohnmilena athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT delordmarc athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT chbatmaureen athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT guemricheamina athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT merabetfatiha athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT roupieannelaure athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT lombionnaelle athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT farhathassan athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT longvalthomas athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT cabanneshamyaurelie athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT lambertjuliette athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT marquejuilletstephanie athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT raggueneauvictoria athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT osmanjennifer athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT spentchianmarc athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT rigaudeausophie athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT rousselotphilippe athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT bessoncaroline athirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT kohnmilena thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT delordmarc thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT chbatmaureen thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT guemricheamina thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT merabetfatiha thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT roupieannelaure thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT lombionnaelle thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT farhathassan thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT longvalthomas thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT cabanneshamyaurelie thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT lambertjuliette thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT marquejuilletstephanie thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT raggueneauvictoria thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT osmanjennifer thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT spentchianmarc thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT rigaudeausophie thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT rousselotphilippe thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia AT bessoncaroline thirdantisarscov2mrnadosedoesnotovercomethepejorativeimpactofanticd20therapyandorlowimmunoglobulinlevelsinpatientswithlymphomaorchroniclymphocyticleukemia |